LOQTORZI
(Toripalimab-tpzi)Phase 2Small molecule
LOQTORZI is one of 32 small molecule programs targeting Ovarian Cancer. It is currently in Phase 2.
1
Indications
2
Total Trials
2
Active Trials
31
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
836 competitors in Ovarian Cancer
#DrugCompanyPhaseTrials
1Hycamtin
MMeitheal
Phase 3
Perjeta
RochePhase 3
Aromasin
PfizerPhase 3
Sacituzumab Tirumotecan
Merck & Co.Phase 3
SHR-A1811
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Phase 3
Chemotherapy Drug
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Phase 3
Azenosertib
KK-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.
Phase 3
JSKN003
JJiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 3
Doxorubicin HCL Liposome
AAccelerated Community Oncology Research Network
Phase 3
In Vitro Sensitivity-Directed Chemotherapy
CChildren's Oncology Group
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Regulatory
FDA Approval Timeline[4]
Oct 27, 2023
LOQTORZI
BLA BLA761240
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Toripalimab-tpzi. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- CCoherus Oncology, Inc.